Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
The Hematologic Malignancy Center at Dana-Farber/Boston Children's Cancer and Blood Disorders Center is one of the top pediatric leukemia and lymphoma treatment centers in the world. In addition to treating blood cancers – lymphomas and leukemias – our
Center also treats histiocytosis, a condition that shares some of the characteristics of cancer and is often treated by using some of the same therapies.
See the full list of the conditions we treat.
Our Center has played a key role in refining treatment for childhood leukemia, resulting in today's cure rates of more than 90 percent for pediatric acute lymphoblastic leukemia, and we continue to lead high-impact clinical trials designed to increase
cure rates and decrease treatment-related toxicities for long-term survivors.
Highlights of the Childhood Hematologic Malignancy Center include:
New Patient Appointments
Find answers to common questions about clinical trials for
childhood cancer, including whether or not a clinical trial may be the right
choice for your child. You can also email your questions to email@example.com